 Zacks Investment Research upgraded shares of Eidos Therapeutics NASDAQ:EIDX from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. The firm currently has 63.00 price target on the stock. According to Zacks, Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral ... 